Submission of Intimation of Allotment of Equity Shares.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Novelix Pharmaceuticals has allotted 11,50,000 equity shares at Rs. 20 each (face value Rs. 10 + premium of Rs. 10) to promoter-group entities upon conversion of warrants. The allottees are Srinidhi Fine-Chemicals LLP (11,00,000 shares) and Narahari Belide (50,000 shares). The company received Rs. 1.72 crore (75% of issue price) from this conversion. These warrants were originally issued on a preferential basis on 10 January 2025; with this conversion, 8,815,000 out of 15,000,000 warrants have now been converted. The company's paid-up equity capital has risen from Rs. 1.99 crore to Rs. 2.11 crore.
This is a promoter-group warrant conversion, meaning existing warrants held by promoters are being exercised into shares. It is mildly dilutive for non-promoter shareholders but signals promoter confidence since insiders are putting in additional capital at a premium to face value.